Additionally, this increased ratio can also be modulated using glucagon receptor antagonists, which were explored recently in a randomised, double-blind, placebo-controlled crossover trial by Boeder et al. in which they compared SGLT-2 inhibitor therapy in patients with type 1 diabetes with the combination of SGLT-2 inhibitors and glucagon receptor antagonists. Here, SLC5A2 is linked to type 1 diabetes mellitus.